November 16, 2012 8:02 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Impax Laboratories, Inc. (NASDAQ: IPXL) and its wholly owned subsidiary, ThoRxLaboratories, Inc., today confirm that they have initiated a challenge of thepatents listed in the Orange Book in connection with Opana® ER (oxymorphonehydrochloride extended-release tablets, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30mg, and 40 mg).ThoRx filed its Abbreviated New Drug Application (ANDA) containing a paragraphIV certification for a generic version of Opana® ^ ER with the U.S. Food &Drug Administration (FDA). Following receipt of the notice from FDA thatThoRx's ANDA had been accepted for filing, ThoRx notified the New DrugApplication holder and patent owner of its paragraph IV certification.On November 14, 2012, Endo Pharmaceuticals Inc. and Grunenthal GMBH filed suitfor patent infringement against ThoRx Laboratories, Inc. and ImpaxLaboratories, Inc. in the United States District Court for the SouthernDistrict of New York. This action formally initiates the patent challengeprocess under the Hatch-Waxman Act.Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's genericdivision, intends to commercialize the product.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.